Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of “Buy” from Analysts

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has earned an average rating of “Buy” from the ten research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have given a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $20.89.

Several research firms recently issued reports on YMAB. HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday, January 13th. Wedbush reissued an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a report on Friday, January 10th. Brookline Capital Management initiated coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They set a “buy” rating and a $17.00 target price for the company. Finally, Oppenheimer assumed coverage on Y-mAbs Therapeutics in a research report on Monday, November 18th. They issued an “outperform” rating and a $23.00 target price on the stock.

Y-mAbs Therapeutics Trading Down 2.8 %

Shares of YMAB stock opened at $5.80 on Tuesday. Y-mAbs Therapeutics has a twelve month low of $5.71 and a twelve month high of $20.90. The stock has a fifty day simple moving average of $8.22 and a two-hundred day simple moving average of $11.48. The stock has a market capitalization of $259.78 million, a price-to-earnings ratio of -10.74 and a beta of 0.69.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The company had revenue of $18.46 million during the quarter, compared to analysts’ expectations of $23.38 million. During the same quarter last year, the firm earned ($0.18) EPS. Research analysts predict that Y-mAbs Therapeutics will post -0.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Y-mAbs Therapeutics during the third quarter worth approximately $44,000. China Universal Asset Management Co. Ltd. increased its stake in Y-mAbs Therapeutics by 66.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock valued at $113,000 after buying an additional 3,416 shares during the period. Intech Investment Management LLC purchased a new position in Y-mAbs Therapeutics during the 3rd quarter worth $133,000. SG Americas Securities LLC lifted its stake in shares of Y-mAbs Therapeutics by 30.7% in the 4th quarter. SG Americas Securities LLC now owns 17,729 shares of the company’s stock worth $139,000 after acquiring an additional 4,163 shares during the period. Finally, Principal Financial Group Inc. boosted its holdings in shares of Y-mAbs Therapeutics by 9.4% in the fourth quarter. Principal Financial Group Inc. now owns 22,197 shares of the company’s stock valued at $174,000 after acquiring an additional 1,903 shares in the last quarter. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.